Cambridge Investment Research Advisors
RNXT icon

Cambridge Investment Research Advisors’s RenovoRx RNXT Stock Holding History

Cambridge Investment Research Advisors’s Portfolio RNXT Stock Details RNXT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-14,900
Closed -$52K – 3271
2023
Q1 		$52K Buy
14,900
+500
+3% +$1.76K ﹤0.01% 3033
2022
Q4 		$34K Hold
14,400
– – ﹤0.01% 3017
2022
Q3 		$29K Hold
14,400
– – ﹤0.01% 2983
2022
Q2 		$29K Hold
14,400
– – ﹤0.01% 2977
2022
Q1 		$42K Hold
14,400
– – ﹤0.01% 3089
2021
Q4 		$70K Sell
14,400
-26,450
-65% -$157K ﹤0.01% 3071
2021
Q3 		$247K Buy
+40,850
New +$340K ﹤0.01% 2629

Other funds holding RNXT

LBC
Lawrence B. Cohen $2.06M AUM 34.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LFAS
Level Four Advisory Services Dallas, Texas $3.54B AUM 37.12% 1-Year Est. Return
ACA
Affinity Capital Advisors Berkeley, California $810M AUM 24.85% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Cambridge Investment Research Advisors's RNXT Position: Q2 2023 in Review

Cambridge Investment Research Advisors sold out of RenovoRx (RNXT) in Q2 2023, closing a stake of 14,900 shares — an estimated $52K sold.

Cambridge Investment Research Advisors first reported a position in RNXT in Q3 2021 and held it in 7 quarters. The position peaked at $247K in Q3 2021. 9 funds tracked by Wall St. Rank hold RNXT as of Q2 2023.

  • Cambridge Investment Research Advisors reported no remaining RenovoRx position as of Q2 2023 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 14,900 RenovoRx shares in Q2 2023, an estimated $52K.
  • Cambridge Investment Research Advisors first reported a position in RenovoRx in Q3 2021 and held it in 7 quarters.
  • Cambridge Investment Research Advisors's RenovoRx position peaked at $247K in Q3 2021.
  • 9 funds tracked by Wall St. Rank held RenovoRx as of Q2 2023.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2023, filed 13 Jul 2023.